Related Experiment Video
Updated: Mar 23, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Recent Advances in Antiviral Therapy for Chronic Hepatitis C
Akihiro Tamori1, Masaru Enomoto1, Norifumi Kawada1
1Department of Hepatology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
Abstract:
Hepatitis C virus (HCV) infection is a major worldwide health problem. Chronic infection induces continuous inflammation in the liver, progression of hepatic fibrosis, eventual cirrhosis, and possible hepatocellular carcinoma. Eradication of the virus is one of the most important treatment aims. A number of promising new direct-acting antivirals (DAAs) have been developed over the past 10 years. Due to their increased efficacy, safety, and tolerability, interferon-free oral therapies with DAAs have been approved for patients with HCV, including those with cirrhosis. This review introduces the characteristics and results of recent clinical trials of several DAAs: NS3/4A protease inhibitors, NS5A inhibitors, and NS5B inhibitors. DAA treatment failure and prognosis after DAA therapy are also discussed.
More Related Videos
Related Concept Videos
Hepatitis
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Retroviruses
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Subviral Agents

